Veropharm, one of Russia’s largest drug makers, saw initial entertain 2012 net distinction boost 46.1 percent year-on-year to 494.3 million rubles ($15 million) to IFRS, a association pronounced on Tuesday.
The company’s income for a entertain grew by 18 percent year-on-year to 1.63 billion rubles.
EBITDA rose 20.2 percent in a initial 3 months of 2012 to 499.5 million rubles, while EBITDA domain increasing to 30.6 percent from 30.0 percent, Veropharm said.
Veropharm’s bound collateral investment soared 189 percent year-on-year to 137 million rubles.
The company’s debt stood during 704.4 million rubles as of a finish of a initial entertain of 2012 and stayed within 20 percent of the net item value.
